Elekta Valuation

Q: What is the Fair Price of EKTA B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

EKTA B (SEK65.5) is trading below our estimate of [[fair value]] (SEK108.33)

Is EKTA B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EKTA B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: EKTA B (SEK65.5) is trading below our estimate of fair value (SEK108.33)

Significantly Below Fair Value: EKTA B is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EKTA B?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for EKTA B. This is calculated by dividing EKTA B's market cap by their current preferred multiple.
What is EKTA B's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	SEK 25.47b

EKTA B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.7x
Enterprise Value/EBITDA	10.3x
PEG Ratio	1.4x

Price to Earnings Ratio vs Peers

How does EKTA B's PE Ratio compare to its peers?

The above table shows the PE ratio for EKTA B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	47.5x
GETI B Getinge	21.5x	12.7%	SEK 49.4b
ARJO B Arjo	22.2x	20.9%	SEK 11.1b
CEVI CellaVision	42.1x	24.0%	SEK 5.9b
ELOS B Elos Medtech	104.3x	n/a	SEK 5.7b
EKTA B Elekta	19.2x	14.4%	SEK 25.2b

Price-To-Earnings vs Peers: EKTA B is good value based on its Price-To-Earnings Ratio (19.2x) compared to the peer average (47.5x).

Price to Earnings Ratio vs Industry

How does EKTA B's PE Ratio compare vs other companies in the European Medical Equipment Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	25.0%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	25.0%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: EKTA B is good value based on its Price-To-Earnings Ratio (19.2x) compared to the European Medical Equipment industry average (30.3x).

Price to Earnings Ratio vs Fair Ratio

What is EKTA B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EKTA B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	19.6x
Fair PE Ratio	24.2x

Price-To-Earnings vs Fair Ratio: EKTA B is good value based on its Price-To-Earnings Ratio (19.2x) compared to the estimated Fair Price-To-Earnings Ratio (24.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EKTA B forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	SEK 66.65	SEK 76.38 +14.6%	24.7%	SEK 127.00	SEK 57.00	n/a	13
Jun ’25	SEK 86.15	SEK 84.08 -2.4%	24.4%	SEK 127.00	SEK 57.00	n/a	12
May ’25	SEK 79.20	SEK 83.42 +5.3%	24.5%	SEK 127.00	SEK 57.00	n/a	12
Apr ’25	SEK 80.70	SEK 86.00 +6.6%	23.7%	SEK 127.00	SEK 57.00	n/a	12
Mar ’25	SEK 77.84	SEK 86.33 +10.9%	23.4%	SEK 127.00	SEK 57.00	n/a	12
Feb ’25	SEK 78.54	SEK 86.67 +10.3%	23.4%	SEK 127.00	SEK 57.00	n/a	12
Jan ’25	SEK 82.32	SEK 84.73 +2.9%	23.3%	SEK 127.00	SEK 57.00	n/a	11
Dec ’24	SEK 82.08	SEK 84.91 +3.4%	23.7%	SEK 127.00	SEK 57.00	n/a	11
Nov ’24	SEK 75.82	SEK 82.00 +8.2%	26.2%	SEK 127.00	SEK 53.00	n/a	11
Oct ’24	SEK 74.42	SEK 83.30 +11.9%	26.6%	SEK 127.00	SEK 53.00	n/a	10
Sep ’24	SEK 77.62	SEK 83.30 +7.3%	26.6%	SEK 127.00	SEK 53.00	n/a	10
Aug ’24	SEK 85.18	SEK 83.20 -2.3%	26.2%	SEK 127.00	SEK 57.00	n/a	10
Jul ’24	SEK 83.34	SEK 85.50 +2.6%	26.0%	SEK 127.00	SEK 57.00	SEK 65.90	10
Jun ’24	SEK 81.62	SEK 83.40 +2.2%	25.5%	SEK 127.00	SEK 57.00	SEK 86.15	10
May ’24	SEK 86.06	SEK 81.22 -5.6%	28.3%	SEK 127.00	SEK 57.00	SEK 79.20	10
Apr ’24	SEK 79.08	SEK 81.22 +2.7%	28.3%	SEK 127.00	SEK 57.00	SEK 80.70	10
Mar ’24	SEK 80.62	SEK 77.91 -3.4%	28.7%	SEK 127.00	SEK 57.00	SEK 77.84	9
Feb ’24	SEK 76.46	SEK 73.67 -3.7%	31.5%	SEK 127.00	SEK 52.00	SEK 78.54	9
Jan ’24	SEK 62.80	SEK 70.44 +12.2%	31.8%	SEK 127.00	SEK 52.00	SEK 82.32	9
Dec ’23	SEK 63.18	SEK 72.75 +15.1%	32.5%	SEK 127.00	SEK 52.00	SEK 82.08	8
Nov ’23	SEK 57.50	SEK 76.13 +32.4%	29.6%	SEK 127.00	SEK 55.00	SEK 75.82	8
Oct ’23	SEK 56.86	SEK 80.43 +41.5%	27.1%	SEK 127.00	SEK 59.00	SEK 74.42	7
Sep ’23	SEK 59.00	SEK 80.43 +36.3%	27.1%	SEK 127.00	SEK 59.00	SEK 77.62	7
Aug ’23	SEK 71.32	SEK 85.29 +19.6%	23.9%	SEK 127.00	SEK 69.00	SEK 85.18	7
Jul ’23	SEK 72.22	SEK 86.14 +19.3%	25.8%	SEK 133.00	SEK 69.00	SEK 83.34	7

Analyst Forecast: Target price is less than 20% higher than the current share price.